Unravelling the Role of Serum Kallistatin on Cardiorenal Outcomes in Kidney Transplant Survivors
Introduction: Kallistatin, a serine protease inhibitor, has been implicated in cardiovascular and renal protection. This study investigates its association with clinical characteristics and outcomes in long-term kidney transplant recipients (KTRs). Methods: In this longitudinal observatio...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Kidney & Blood Pressure Research |
| Online Access: | https://karger.com/article/doi/10.1159/000543652 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133681092427776 |
|---|---|
| author | Krzysztof Batko Anna Sączek Małgorzata Banaszkiewicz Jolanta Małyszko Ewa Koc-Żórawska Marcin Żórawski Karolina Niezabitowska Katarzyna Siek Andrzej Kraśniak Marcin Krzanowski Katarzyna Krzanowska |
| author_facet | Krzysztof Batko Anna Sączek Małgorzata Banaszkiewicz Jolanta Małyszko Ewa Koc-Żórawska Marcin Żórawski Karolina Niezabitowska Katarzyna Siek Andrzej Kraśniak Marcin Krzanowski Katarzyna Krzanowska |
| author_sort | Krzysztof Batko |
| collection | DOAJ |
| description |
Introduction: Kallistatin, a serine protease inhibitor, has been implicated in cardiovascular and renal protection. This study investigates its association with clinical characteristics and outcomes in long-term kidney transplant recipients (KTRs). Methods: In this longitudinal observational cohort study, we enrolled 101 KTRs between September 2016 and October 2017. The median (interquartile range) time post-transplant was 52 (36–97) months, and the follow-up time was 83 (41–85) months. All patients had documented graft function of ≥24 months and no record of acute rejection or active or chronic infection at presentation. Serum kallistatin and high-sensitivity interleukin-6 were measured at baseline using commercially available enzyme-linked immunosorbent assays. A control group of 32 healthy volunteers was also recruited. Results: Higher serum kallistatin levels were observed in KTRs compared to healthy controls (15.9 vs. 13.8 µg/mL; p = 0.007). Concentrations were lower in diabetic versus non-diabetic KTR (14.8 vs. 16.4 µg/mL; p = 0.021). A significant interaction between diabetic status and body mass index indicated a positive association with kallistatin levels only in diabetic KTRs (p = 0.046). Linear mixed models assessing estimated glomerular filtration rate (eGFR) change over time showed improved fit after kallistatin was included in a base model with age, sex, and baseline eGFR (p = 0.024). Cox regression showed that higher kallistatin levels were associated with an increased risk of graft loss (HR: 1.120; p = 0.049), but also remained independent of time after transplantation (HR: 1.147; p = 0.030). No association was observed for all-cause mortality. The best performance was estimated for kallistatin models adjusting for time post-transplant (c-index 0.779) and diabetic status (c-index 0.707). Conclusion: This study highlights the complex interactions between kallistatin, renal function, and cardiometabolic status in stable, long-term KTRs. Higher kallistatin levels are associated with an increased risk of graft loss in non-diabetic patients while showing a protective effect in diabetic patients. These findings support integrated management of cardio-reno-metabolic health in KTRs. |
| format | Article |
| id | doaj-art-5c74c7ca8d704ac3adc2f03a40c84ebe |
| institution | OA Journals |
| issn | 1423-0143 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Kidney & Blood Pressure Research |
| spelling | doaj-art-5c74c7ca8d704ac3adc2f03a40c84ebe2025-08-20T02:31:55ZengKarger PublishersKidney & Blood Pressure Research1423-01432025-01-0150122123110.1159/000543652Unravelling the Role of Serum Kallistatin on Cardiorenal Outcomes in Kidney Transplant SurvivorsKrzysztof BatkoAnna SączekMałgorzata BanaszkiewiczJolanta MałyszkoEwa Koc-ŻórawskaMarcin ŻórawskiKarolina NiezabitowskaKatarzyna SiekAndrzej KraśniakMarcin KrzanowskiKatarzyna Krzanowska Introduction: Kallistatin, a serine protease inhibitor, has been implicated in cardiovascular and renal protection. This study investigates its association with clinical characteristics and outcomes in long-term kidney transplant recipients (KTRs). Methods: In this longitudinal observational cohort study, we enrolled 101 KTRs between September 2016 and October 2017. The median (interquartile range) time post-transplant was 52 (36–97) months, and the follow-up time was 83 (41–85) months. All patients had documented graft function of ≥24 months and no record of acute rejection or active or chronic infection at presentation. Serum kallistatin and high-sensitivity interleukin-6 were measured at baseline using commercially available enzyme-linked immunosorbent assays. A control group of 32 healthy volunteers was also recruited. Results: Higher serum kallistatin levels were observed in KTRs compared to healthy controls (15.9 vs. 13.8 µg/mL; p = 0.007). Concentrations were lower in diabetic versus non-diabetic KTR (14.8 vs. 16.4 µg/mL; p = 0.021). A significant interaction between diabetic status and body mass index indicated a positive association with kallistatin levels only in diabetic KTRs (p = 0.046). Linear mixed models assessing estimated glomerular filtration rate (eGFR) change over time showed improved fit after kallistatin was included in a base model with age, sex, and baseline eGFR (p = 0.024). Cox regression showed that higher kallistatin levels were associated with an increased risk of graft loss (HR: 1.120; p = 0.049), but also remained independent of time after transplantation (HR: 1.147; p = 0.030). No association was observed for all-cause mortality. The best performance was estimated for kallistatin models adjusting for time post-transplant (c-index 0.779) and diabetic status (c-index 0.707). Conclusion: This study highlights the complex interactions between kallistatin, renal function, and cardiometabolic status in stable, long-term KTRs. Higher kallistatin levels are associated with an increased risk of graft loss in non-diabetic patients while showing a protective effect in diabetic patients. These findings support integrated management of cardio-reno-metabolic health in KTRs. https://karger.com/article/doi/10.1159/000543652 |
| spellingShingle | Krzysztof Batko Anna Sączek Małgorzata Banaszkiewicz Jolanta Małyszko Ewa Koc-Żórawska Marcin Żórawski Karolina Niezabitowska Katarzyna Siek Andrzej Kraśniak Marcin Krzanowski Katarzyna Krzanowska Unravelling the Role of Serum Kallistatin on Cardiorenal Outcomes in Kidney Transplant Survivors Kidney & Blood Pressure Research |
| title | Unravelling the Role of Serum Kallistatin on Cardiorenal Outcomes in Kidney Transplant Survivors |
| title_full | Unravelling the Role of Serum Kallistatin on Cardiorenal Outcomes in Kidney Transplant Survivors |
| title_fullStr | Unravelling the Role of Serum Kallistatin on Cardiorenal Outcomes in Kidney Transplant Survivors |
| title_full_unstemmed | Unravelling the Role of Serum Kallistatin on Cardiorenal Outcomes in Kidney Transplant Survivors |
| title_short | Unravelling the Role of Serum Kallistatin on Cardiorenal Outcomes in Kidney Transplant Survivors |
| title_sort | unravelling the role of serum kallistatin on cardiorenal outcomes in kidney transplant survivors |
| url | https://karger.com/article/doi/10.1159/000543652 |
| work_keys_str_mv | AT krzysztofbatko unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT annasaczek unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT małgorzatabanaszkiewicz unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT jolantamałyszko unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT ewakoczorawska unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT marcinzorawski unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT karolinaniezabitowska unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT katarzynasiek unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT andrzejkrasniak unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT marcinkrzanowski unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors AT katarzynakrzanowska unravellingtheroleofserumkallistatinoncardiorenaloutcomesinkidneytransplantsurvivors |